Omeprazole vs Lansoprazole in the Management of Gastroesophageal Reflux Disease: A Systematic Literature Review

Mamoona Javed¹, Muhammad Hayder Ali², Muhammad Saad Tanveer³, Muhammad Hassan Tanveer⁴

Affiliations:
¹Mamoona Javed (MPhil, MSc), Parim Evidencia Ltd, 321-323 High Road, Romford, London, RM6 6AX, UK.
²Muhammad Hayder Ali (PhD, MPhil), Parim Evidencia Ltd, 321-323 High Road, Romford, London, RM6 6AX, UK.
³Muhammad Saad Tanveer, Parim Evidencia Ltd, 321-323 High Road, Romford, London, RM6 6AX, UK.
⁴Muhammad Hassan Tanveer, Parim Evidencia Ltd, 321-323 High Road, Romford, London, RM6 6AX, UK.

Corresponding Author
Mamoona Javed, 321-323 High Road, Romford, RM6 6AX, London, United Kingdom
Tel: 0044 7806 079975, Email: mamoonajav@gmail.com

Accepted and to be published in Journal of Medical Research and Innovation

Article details:
DOI : 10.32892/jmri.204
Volume & Issue : Vol 4 No 2 (2020): Article in Press
Page No.: e000204
Received: 15-01-2020, Accepted: 14-02-2020, Published: 29-03-2020

Cite as:
Javed M, Ali MH, Tanveer MS, Tanveer MH. Omeprazole vs Lansoprazole in the Management of Gastroesophageal Reflux Disease: A Systematic Literature Review. J Med Res Innov. 2020;4(2):e000204.
DOI: 10.32892/jmri.204

Copyrights: @ Authors.

Creative Commons License: This work is licensed under a Creative Commons Attribution 4.0 International License.

Please note: This is the author's final version and shall now undergo copyediting and typesetting. There may be some changes in the final publication if errors are found during the copyediting process.
# CONTENTS

Abstract.............................................................................................................................................4

1. Introduction ....................................................................................................................................5
   1.1. Objective..................................................................................................................................6

2. Methods.........................................................................................................................................6
   2.1. Criteria for considering studies for this review.................................................................6
   2.2. Data sources and search strategy .........................................................................................7
   2.3. Study selection.......................................................................................................................7
   2.4. Data Extraction......................................................................................................................8

3. Results...........................................................................................................................................8
   3.1. Participants and study designs............................................................................................8
   3.2. Interventions........................................................................................................................9
   3.3. Outcomes.............................................................................................................................9

4. Discussion.....................................................................................................................................13

5. Conclusions..................................................................................................................................14

6. References.....................................................................................................................................15

7. Supplementary Material .............................................................................................................17
LIST OF TABLES AND FIGURES

Table 1. Total number of studies identified from database searches .................................................. 19
Table 2. Inclusion and Exclusion criteria .......................................................................................... 20
Table 3. Characteristics of studies included in this review ............................................................... 12
Figure 1. PRISMA Flow diagram ....................................................................................................... 11
Figure 2. Risk of Bias graph ............................................................................................................. 22
Figure 3. Risk of Bias summary ........................................................................................................ 23
Search strategy ............................................................................................................................... 17
Abbreviations ..................................................................................................................................... 24
ABSTRACT

Objective: To evaluate the effectiveness and safety of omeprazole compared to lansoprazole in Gastroesophageal reflux disease patients (GERD).

Methods: A systematic search of MEDLINE, EMBASE (inception to December 2019) and CENTRAL (January 2011 to December 2019) was conducted to identify the relevant articles. A detailed inclusion-exclusion criterion was developed and implemented to screen the abstracts. Full texts of the selected abstracts were then assessed to establish their inclusion or exclusion in our review. Cochrane risk of bias criterion was used to assess the methodological quality of the included studies. All relevant data were extracted and the results were summarised narratively.

Results: 9 studies met our inclusion-exclusion criteria and were included in this review. Heartburn and regurgitation: In all three trials reporting on heartburn and regurgitation, both omeprazole and lansoprazole were found to be effective in relieving the symptoms of heartburn and regurgitation; however, there was no evidence that one is better than the other. Intragastric pH: Five out of six studies reporting on intragastric pH provided the evidence of omeprazole’s superiority over lansoprazole in controlling gastric pH. Omeprazole lowered intragastric pH faster and the results lasted longer compared to lansoprazole. The results were statistically significant.

Conclusion: There is no significant difference in the clinical effectiveness of omeprazole and lansoprazole in relieving symptoms of heartburn and regurgitation. However, omeprazole is more effective in reducing gastric acidity than lansoprazole.

Keywords: Gastroesophageal reflux disease, omeprazole, lansoprazole, heartburn, regurgitation, intragastric pH
1. INTRODUCTION

Gastroesophageal reflux disease (GERD) is a digestive disorder. The condition results from the reflux of gastric contents into the esophagus[1]. Gastroesophageal reflux (GER) is a common condition and is experienced occasionally by a large population. However, if GER occurs persistently more than twice a week, the condition is diagnosed as GERD[2]. GERD is divided into two categories: non-erosive esophageal reflux disease (NERD) and erosive reflux disease, also called erosive esophagitis (EE).

Frequent flow back of stomach contents into esophagus can irritate the lining of the esophagus[3]. Prevalence of GERD varies remarkably throughout the world, with a pooled prevalence of 13.3% worldwide[4]. However, the prevalence is significantly higher in western countries (20-30%) as compared to Asia (5%). Korea has seen a rise in GERD prevalence in recent year with the latest prevalence figure at 10%, probably attributed by western diet styles[5].

Heartburn and regurgitation are the main symptoms in GERD. The patients may also suffer from one or more of the following symptoms: bad breath, feeling sick, bloating, chest pain, difficult swallowing, tooth decay and sensation of a lump in the throat. Nighttime acid reflux may disrupt sleep, as well[6]. GERD is caused by frequent acid reflux. The condition occurs because of the dysfunctioning of the lower esophageal sphincter (LES) (the ring of muscles at the bottom of the esophagus, between esophagus and stomach). LES plays a vital role in the digestive system. Its opening and closing allow food to pass into the stomach and prevents backflow of stomach contents into the esophagus. GERD occurs when LES fails to function appropriately and allows stomach contents backflow into esophagus either by not closing fully or by opening at wrong times[7]. Though the cause of weakening of this ring is not always clear, certain factors can increase the risk of this happening. These factors include: eating unhealthy or fatty foods in large quantities, being overweight, smoking and alcohol, hiatus hernia and certain medicines. In addition to these, stress and hormonal changes also increase the risk of developing GERD[6].

GERD is usually treated through self-help measures and acid suppressant medications. Self-help measures include changes in lifestyle. GERD patients can manage their condition significantly by adopting following style measures: cutting down on eating fatty, sweet and spicy food; stop eating before being full, avoiding smoking and alcohol, and reducing coffee consumption. In addition to these, maintaining a correct posture and avoid wearing tight clothes helps to improve the symptoms. Losing weight helps to resolve GERD symptoms in addition to reducing the risk of several other medical conditions like diabetes, hypertension and cardiovascular diseases[8].
Lifestyle interventions are highly effective for improving reflux symptoms in GERD patients. However, they may not resolve all the symptoms of GERD, and the patients may need pharmacological interventions to solve this medical problem. The most commonly prescribed medication for GERD is Proton Pump Inhibitors (PPI). PPI is a group of medication that reduce the secretion of stomach acid. PPIs are among the most widely used GERD medications in the world and are considered the most effective treatment of GERD[9]. The first one, omeprazole, is on the WHO Model List of Essential Medicines[10]. There are several PPIs available. Omeprazole and lansoprazole have been available the longest and are among the most commonly used medicines. Although they are structurally and chemically similar, there are relatively few comparisons of these drugs with each other[11]. Moreover, they respond differently in different patients and may not be suitable for every patient. The side effects of both of these drugs also vary from patient to patient. There is no systematic review to compare the safety and effectiveness of omeprazole and lansoprazole. We are, therefore conducting this systematic review to identify the studies comparing the effectiveness and safety of omeprazole and lansoprazole.

1.1. Objective
There were two objectives of this systematic review:

- To evaluate the effectiveness and safety of omeprazole compared to lansoprazole in GERD patients.
- To highlight the gap in the evidence.

2. METHODS
This systematic review was conducted to identify evidence comparing the efficacy and safety of omeprazole and lansoprazole. We followed PRISMA reporting guidelines (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) for this systematic literature review[12]. We aimed to apply a rigorous and transparent methodology to reduce bias in the selection of relevant studies.

2.1. Criteria for considering studies for this review

Eligibility criteria
Eligibility criteria for including studies for this systematic literature review were:

Type of studies
All published randomised controlled trials, including cluster and cross-over trials, were eligible for inclusion in this systematic review. In addition to this, non-randomised clinical
trials, cohort, case-control, cross-sectional studies and systematic reviews were also eligible for inclusion. Systematic reviews were included for cross-referencing. We, however, excluded letters to the editor, narrative reviews, editorials, expert opinions, case studies, case series.

**Types of participants**
Adult patients (over 18 years) with non-erosive esophageal reflux disease (NERD) were included in this systematic review. We excluded studies investigating patients with other conditions, including erosive esophagitis (EE). Studies on adolescents and children under the age of 18 years, including neonates and infants with NERD, were excluded. We also excluded the studies focusing on treating NERD symptoms in patients with other diseases.

**Types of interventions**
Studies comparing omeprazole and lansoprazole were included in this systematic review.

**Outcomes**
The primary outcomes were heartburn and regurgitation. The secondary outcomes were intragastric pH and treatment-emergent adverse effects.

### 2.2. Data sources and search strategy
We systematically searched three databases; Medline, Embase and Cochrane Central Register of Controlled Trials (CENTRAL) for this review. Medline and Embase were searched through ProQuest from inception to December 2019 while CENTRAL was searched to retrieve the relevant literature of the past nine years (January 2011 to December 2019). The search strategy used for Medline and Embase is reported in the Supplementary Materials and was constructed from search terms relating to GERD, to omeprazole and lansoprazole. The search was narrowed by applying filters to limit the studies only to abstracts, English language and human. The search was not limited by age group at this stage. The reference lists of relevant studies were also screened to identify other relevant studies. The search results were downloaded and imported in reference management software ‘Zotero’.

### 2.3. Study selection
The studies were screened in abstract screening software ‘Rayyan’[13] by two researchers by title and abstracts and discrepancies were resolved through discussion. Primary research studies and systematic reviews relevant to patients with GERD, reporting intervention effectiveness and safety outcomes and published in English were included in our research. We excluded all children and infants studies. The inclusion and exclusion criteria are reported in full in Table 2 in Supplementary Materials.
The full texts were retrieved for all studies that met the inclusion criteria for the title and abstract screening. Full-texts were screened using the same inclusion criteria as abstract screening but focused on identifying studies with clinically relevant outcomes. Two researchers independently conducted full-text screening and resolved the disagreements through discussion.

2.4. Data extraction
A pre-agreed MS Excel template was used to extract the relevant data. The data from the included studies were extracted by one reviewer, and all data extraction tables were checked by a second reviewer. All included studies were assessed for methodological quality using the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions[14]. The results were synthesised narratively to identify common themes and gaps in the evidence.

3. RESULTS
The database search of MEDLINE, EMBASE and Cochrane Central Register of Controlled Trials (CENTRAL) identified 2,161 citations, of which 635 were duplicates, leaving 1,526 unique citations for screening (Table 1). We identified many studies that compared omeprazole or lansoprazole with other interventions, but the evidence base on the direct comparative effectiveness of omeprazole and lansoprazole was limited. Twenty-one articles were identified as potentially meeting the inclusion criteria and were retrieved as full texts, and 9 of these were subsequently included in the review (Figure 1).

3.1. Participants and Study Designs
Nine studies included in the systematic review all described primary research on GERD symptoms. Two of these studies were conducted on healthy volunteers[15], [16] while all others were conducted on GERD patients. Six studies included in this review were the primary reports of the randomised cross-over studies[15], [17]–[21]; of these, one study was randomised double-blinded clinical trial[16]; one was randomised, parallel-group comparative study[22]; one was randomised, open-label trial[21] and one was randomised clinical study[23].

All subjects were adults (over 18 years) males and females. All included studies reported our outcomes of interest. The study characteristics of included studies are reported in Table 3. Nine studies reporting on our outcomes of interest enrolled a total of 418 participants, undergoing omeprazole and lansoprazole treatment at 1:1 ratio in parallel studies. In all studies, baseline characteristics were comparable between the two interventions.
3.2. Interventions

Patients were treated with 20 mg omeprazole and 30 mg lansoprazole in crossover trials in Funaki et al. (2013)[17], Katz et al. (2000)[15] and Janczewska et al. (1998)[20]. In Katz et al. (2001), the subjects were divided into two separate trials; study 1 and study 2. In study 1, the subjects were assigned 20 mg omeprazole and 30 mg lansoprazole while in study 2, the subjects were offered 40 mg omeprazole and 30 mg lansoprazole. An equal number of subjects were treated first with omeprazole or lansoprazole in this crossover trial. The drugs were administered openly but in random order in each trial[19].

Miner et al. (2010) administered 20.6 mg omeprazole and 15 mg lansoprazole in healthy volunteers in a randomised double-blind trial to establish the superiority of one drug over the other one[16].

Vivian et al. (1999) randomised the patients into two groups using a random number chart in this crossover study. One group received omeprazole 20 mg once daily for two weeks then omeprazole 40 mg once daily for an additional two weeks while the other group received lansoprazole 15 mg once daily for two weeks then lansoprazole 30-mg once daily for an additional two weeks. Both groups switched over the medication after one-week washout[18].

Fass et al. (2000) administered 40 mg omeprazole and 30 mg lansoprazole in severe symptomatic GERD patients for six weeks to determine the clinical effectiveness of these interventions[22].

Arezoomandi et al. (2019) administered 40 mg omeprazole and 30 mg lansoprazole for eight weeks to evaluate the effects of omeprazole and lansoprazole on the symptoms of GERD[23].

Howden et al. (2009) conducted a 3-period cross over study to compare the effects of 40 mg omeprazole, 30 mg lansoprazole and 40 mg pantoprazole on intragastric acidity[21].

3.3. Outcomes

Heartburn and regurgitation: Three studies reported on heartburn and regurgitation[18], [22], [23]. Arezoomandi et al. (2019) reported a significant reduction in heartburn and regurgitation between 0 and 8 weeks of treatment (P < 0.001). However, there was not a significant difference between the interventions in reducing GERD symptoms. Fass et al. (2000) reported equal effectiveness and tolerance for omeprazole and lansoprazole in symptom control of patients with GERD. Although both interventions were successful in improving the symptoms, there was no significant evidence that one is better than the other. The outcomes from Vivian et al. (1999) study were similar to the above studies, and the authors were not able to conclude the clinical effectiveness superiority of one intervention over the other.

Gastric pH: Six studies reported on intragastric pH[15]–[17], [19]–[21]; four of these studies were conducted on GERD patient[17], [19]–[21] while two were conducted on healthy
Omeprazole showed a significant increase in pH, compared with lansoprazole (p < 0.05) in Funaki et al. (2013). The patients in Katz et al. (2001) study was divided into two groups. Group 1 was given 30 mg lansoprazole and 20 mg omeprazole while group 2 was given 30 mg lansoprazole and 40 mg omeprazole. The authors found no significant difference in intragastric pH in group 1 patients who were treated with either 30 mg lansoprazole or 20 mg omeprazole. However, in group 2 patients, omeprazole 40 mg provided statistically significantly higher increase in intragastric pH than with lansoprazole 30 mg. Similar results were found in Howden et al. (2009). The authors observed an extended period of high gastric pH (pH>4) with omeprazole than with lansoprazole (P=0.005). Although both drugs were well tolerated, median intragastric pH was significantly higher with omeprazole than with lansoprazole (P=0.003). In contrast to the above three, Janczewska et al. (1998) found lansoprazole 30 mg more effective than omeprazole 20 mg in reducing gastric acidity.

In both studies conducted on healthy volunteers, omeprazole appears to be more effective than lansoprazole in gastric acid control. In healthy volunteers, twice-daily dosing of omeprazole 20 mg appears to be significantly more effective than lansoprazole 30 mg in controlling gastric acidity. The clinical importance of such a difference remains to be defined in GERD patients[15]. Omeprazole-Mg 20.6 mg provided a statistically significantly (P < 0.0001) greater acid control than lansoprazole 15 mg[16]. The authors reported that there were no serious adverse effects.
Figure 1: PRISMA Flow Diagram

1,995 of records identified through PubMed and Embase searching

166 of additional records identified through CENTRAL search

1,526 of records after duplicates removed

1,526 of records screened

1,505 of records excluded

12 of full-text articles excluded for the following reasons:
2 = Population other than GERD
3 = H.Pylori eradication focus
7 = Genotype / metabolizing activity focus

21 of full-text articles assessed for eligibility

9 of studies included in qualitative synthesis
| Reference         | Country | Participants (n) | Male n (%) | Focus of the study                  |
|-------------------|---------|------------------|------------|------------------------------------|
| Arezoomandi et al[23] | Iran    | 120              | NR         | Heartburn and regurgitation        |
| Funaki et al[17]  | Japan   | 10               | NR         | Gastric pH                         |
| Miner et al[16]   | USA     | 40               | 28 (70%)   | Gastric pH                         |
| Fass et al[22]    | USA     | 95               | NR         | Heartburn and regurgitation        |
| Vivian et al[18]  | USA     | 27               | 26 (96%)   | Heartburn and regurgitation        |
| Katz et al[19]    | USA     | 36               | 6 (17%)    | Gastric pH                         |
| Katz et al[15]    | USA     | 20               | 10 (50%)   | Gastric pH                         |
| Howden et al[21]  | USA     | 55               | NR         | Gastric pH                         |
| Janczewska et al[20] | Sweden  | 14               | NR         | Gastric pH                         |
4. Discussion

Rapid acid suppression is vital to control unpleasant reflux symptoms in the treatment of GERD[17]. Omeprazole and lansoprazole are the most commonly used PPIs to treat GERD symptoms. Although there is a risk of increased bacterial growth and spontaneous bacterial peritonitis with PPI therapy[24], they have been proven safe and effective to treat non-erosive reflux disease (NERD). None of the studies in our systematic review reported any serious adverse effects, which also provides evidence that omeprazole and lansoprazole are safe and effective to use at least for a short period. However, this review only focused on NERD, and the implications may be different for erosive reflux disease.

Although no studies in our systematic review have provided any evidence of the superiority of omeprazole and lansoprazole in terms of clinical effectiveness, both interventions were successful in providing heartburn and regurgitation symptoms relief. The effect of these interventions is, however, limited[5]. There is significant evidence that change in lifestyle can improve GERD symptoms[25] and that combining lifestyle interventions with PPIs provide better results[8]. In addition to this, combining omeprazole with other drugs like Baclofen is a more effective treatment for heartburn and regurgitation than omeprazole alone[26]. Increasing the dose may also be an option to increase gastric pH and improve reflux symptoms. However, this, in turn, may change the absorption of trace elements. A study conducted in Iran found significantly lower levels of Zinc (Zn) in males after omeprazole consumption[25].

Omeprazole is also effective in controlling nocturnal acid in patients who suffer from night-time heartburn. A study conducted in the USA concluded that bedtime immediate relief omeprazole (IR-OME) provided more rapid control of night-time gastric pH and decreased nocturnal acid breakthrough (NAB) compared with lansoprazole[28].

All the studies in this review favoured omeprazole in increasing gastric pH and reducing GERD symptoms except one conducted in Sweden by Janczewska et al., however the small sample size (n=14) in this trial makes the results less generalisable. We had not found any other study concluding lansoprazole’s superiority over omeprazole. This does not mean that omeprazole always performs better than lansoprazole. There are several case studies which demonstrate non-tolerability of omeprazole and excellent tolerability and effectiveness of lansoprazole. However, case studies were excluded to meet inclusion and exclusion criteria of this research. There is a significant evidence base on the superiority of lansoprazole when compared with other interventions or placebo but this review only included the studies which were comparing omeprazole and lansoprazole.

Two-third of the studies in our review were crossover trials. More double-blinded RCTs are needed to establish a true superiority of our interventions. We did not find any observational studies which met our inclusion criterion. Although, RCTs are considered as gold standard, additional evidence from observational studies would not only improve the strength of our evidence but also enhance our understanding regarding long-term use of omeprazole and lansoprazole. Hence, there is a need to design and conduct high quality observational studies.
5. Conclusion
There is no significant difference in the clinical effectiveness of omeprazole and lansoprazole in relieving symptoms of heartburn and regurgitation. However, omeprazole is more effective in increasing intragastric pH than lansoprazole. Both interventions are safe to use with only mild side effects which disappear when discontinued.
6. References

[1] H. Miwa, A. Igarashi, L. Teng, A. Uda, H. Deguchi, and T. Tango, ‘Systematic review with network meta-analysis: indirect comparison of the efficacy of vonoprazan and proton-pump inhibitors for maintenance treatment of gastroesophageal reflux disease’, J. Gastroenterol., vol. 54, no. 8, pp. 718–729, Aug. 2019, doi: 10.1007/s00535-019-01572-y.

[2] M. MacGill, ‘Everything you need to know about GERD. https://www.medicalnewstoday.com/articles/14085.php. Date accessed: 24th Dec 2019.’, 18-Jan-2018.

[3] M. Clinic, ‘Gastroesophageal reflux Disease (GERD). www.mayoclinic.org. Date accessed: 24th Dec 2019.’ 23-Oct-2019.

[4] Y. Xiao et al., ‘Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis’, Gut, 2019, doi: 10.1136/gutjnl-2019-318365.

[5] E. J. Kim et al., ‘Efficacy and safety of AlbisD compared with omeprazole 20 mg in patients with non-erosive reflux disease: A randomized, open-label, active-controlled, pilot study’, J. Neurogastroenterol. Motil., vol. 25, no. 3, pp. 403–412, 2019, doi: 10.5056/jnm18185.

[6] NHS Inform, ‘Gastro-oesophageal reflux disease (GORD). https://www.nhsinform.scot/illnesses-and-conditions/stomach-liver-and-gastrointestinal-tract/gastro-oesophageal-reflux-disease-gord#causes-of-gord. Date accessed: 24th Dec 2019.’ 30-Sep-2019.

[7] WebMD, ‘Gastroesophageal Reflux Disease (GERD). https://www.webmd.com/heartburn-gerd/guide/reflux-disease-gerd-1#1. Date accessed: 24th Dec 2019.’

[8] K. Haruma, Y. Kinoshita, S. Sakamoto, K. Sanada, S. Hiroi, and H. Miwa, ‘Lifestyle factors and efficacy of lifestyle interventions in gastroesophageal reflux disease patients with functional dyspepsia: Primary care perspectives from the LEGEND study’, Intern. Med., vol. 54, no. 7, pp. 695–701, Apr. 2015, doi: 10.2169/internalmedicine.54.3056.

[9] Wikipedia contributors, ‘Proton-Pump Inhibitor. Wikipedia. https://en.wikipedia.org/w/index.php?title=Proton-pump_inhibitor&oldid=935218418. Date accessed: 16th Dec 2019.’ 16-Dec-2019.

[10] WHO, ‘Organization, World Health (2019). “World Health Organization model list of essential medicines: 21st list 2019”. WHO Model List of Essential Medicines, https://en.wikipedia.org/w/index.php?title=WHO_Model_List_of_Essential_Medicines&oldid=93452205. Date accessed: 16th Dec 2019.’

[11] J. Patrick Waring, ‘Proton Pump Inhibitors (PPIs). https://www.aboutgerd.org/medications/proton-pump-inhibitors-ppis.html. Date accessed: 24th Dec 2019.’

[12] Moher D, Liberati A, Tetzlaff J, Altman DG, ‘Journal of Clinical Epidemiology Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. J Clin Epidemiol 2009; doi:10.1016/j.jclinepi.2009.06.005’, J. Clin. Epidemiol.

[13] Mourad Ouzzani, Hossam Hammady, Zbys Fedorowicz, and Ahmed Elmagarmid., ‘Rayyan — a web and mobile app for systematic reviews. Systematic Reviews (2016) 5:210’, doi: 10.1186/s13643-016-0384-4.

[14] Higgins JPT, Green S (editors)., Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org. .

[15] P. O. Katz, J. G. Hatlebakk, and D. O. Castell, ‘Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole’, Aliment. Pharmacol. Ther., vol. 14, no. 6, pp. 709–14, Jun. 2000.

[16] P. B. Miner Jr, L. A. McKean, R. D. Gibb, G. N. Erasala, D. L. Ramsey, and J. W. McRorie, ‘Omeprazole-Mg 20.6 mg is superior to lansoprazole 15 mg for control of gastric acid: a
comparison of over-the-counter doses of proton pump inhibitors’, *Aliment. Pharmacol. Ther.*, vol. 31, no. 8, pp. 846–51, Apr. 2010, doi: 10.1111/j.1365-2036.2010.04258.x.

[17] Y. Funaki *et al.*, ‘Comparison of the effect of a single dose of omeprazole or lansoprazole on intragastric pH in Japanese participants: A two-way crossover study’, *J. Chin. Med. Assoc.*, vol. 76, no. 3, pp. 131–134, Mar. 2013, doi: 10.1016/j.jcma.2012.11.006.

[18] E. Vivian, A. Morreale, E. Boyce, K. Lowry, O. Ereso, and P. Hlavin, ‘Efficacy and cost effectiveness of lansoprazole versus omeprazole in maintenance treatment of symptomatic gastroesophageal reflux disease’, *Am. J. Manag. Care*, vol. 5, no. 7, pp. 881–886, 1999.

[19] P. O. Katz, S. Xue, and D. O. Castell, ‘Control of intragastric pH with omeprazole 20 mg, omeprazole 40 mg and lansoprazole 30 mg’, *Aliment. Pharmacol. Ther.*, vol. 15, no. 5, pp. 647–52, May 2001.

[20] I. Janczewska, M. Sagar, S. Sjöstedt, B. Hammarlund, M. Iwarzon, and R. Seensalu, ‘Comparison of the effect of lansoprazole and omeprazole on intragastric acidity and gastroesophageal reflux in patients with gastroesophageal reflux disease’, *Scand. J. Gastroenterol.*, vol. 33, no. 12, pp. 1239–43, Dec. 1998.

[21] C. W. Howden, E. D. Ballard, F. K. Koch, T. C. Gautille, and R. G. Bagin, ‘Control of 24-hour intragastric acidity with morning dosing of immediate-release and delayed-release proton pump inhibitors in patients with GERD’, *J. Clin. Gastroenterol.*, vol. 43, no. 4, pp. 323–6, Apr. 2009, doi: 10.1097/MCG.0b013e31818a386e.

[22] R. Fass *et al.*, ‘Omeprazole 40 mg once a day is equally effective as lansoprazole 30 mg twice a day in symptom control of patients with gastro-oesophageal reflux disease (GERD) who are resistant to conventional-dose lansoprazole therapy: a prospective, randomized, multi-centre study’, *Aliment. Pharmacol. Ther.*, vol. 14, no. 12, pp. 1595–603, Dec. 2000.

[23] N. Arezoomandi and P. Adibi, ‘Comparison of the effect of omeprazole, pantoprazole, esomeprazole, and lansoprazole on the reduction of symptoms in patients with gastroesophageal reflux disease’, *J. Isfahan Med. Sch.*, vol. 36, no. 507, p. 1498‐1504, 2019, doi: 10.22122/jims.v36i507.10815.

[24] İ. Hatemi and S. N. Esatoğlu, ‘What is the long term acid inhibitor treatment in gastroesophageal reflux disease? What are the potential problems related to long term acid inhibitor treatment in gastroesophageal reflux disease? How should these cases be followed?’, *Turk. J. Gastroenterol.*, vol. 28, pp. S57–S60, 2017, doi: 10.5152/tjg.2017.15.

[25] W. Tarsin, I. Alshamli, E. Alabbasi, E. Naas, and M. Soussi, ‘The relationship between acidic & non acidic gastro esophageal reflux disease (GERD) and asthma’, *Eur. Respir. J.*, vol. 38, Sep. 2011.

[26] M. Abbasinazari *et al.*, ‘Effect of a combination of omeprazole plus sustained release baclofen versus omeprazole alone on symptoms of patients with Gastroesophageal Reflux Disease (GERD)’, *Iran. J. Pharm. Res.*, vol. 13, no. 4, pp. 1221–1226, Sep. 2014.

[27] H. Joshaghanie *et al.*, ‘Effects of omeprazole consumption on serum levels of trace elements’, *J. Trace Elem. Med. Biol.*, vol. 26, no. 4, pp. 234–237, Oct. 2012, doi: 10.1016/j.jtemb.2012.02.002.

[28] P. O. Katz *et al.*, ‘Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms’, *Aliment. Pharmacol. Ther.*, vol. 25, no. 2, pp. 197–205, Jan. 2007.
## Supplementary Material

### Search Strategy for Medline and Embase

| Set# | Searched for                                                                 | Databases | Results |
|------|------------------------------------------------------------------------------|-----------|---------|
| S1   | (MJMESH.EXACT.EXPLODE("Gastroesophageal Reflux"))                           | MEDLINE®  | 19260*  |
| S2   | (ti,ab(GER OR GERD OR GORD))                                                 | MEDLINE®  | 11945*  |
| S3   | (ti,ab("acid reflux" or "chronic acid reflux"))                             | MEDLINE®  | 2366°   |
| S4   | (ti,ab("heart burn and acid reflux"))                                        | MEDLINE®  | 0°      |
| S5   | (ti,ab("gastroesophageal reflux disease" or "gastroesophageal reflux disease")) | MEDLINE®  | 11142*  |
| S6   | (ti,ab("gastroesophageal reflux" or "gastro esophageal reflux"))            | MEDLINE®  | 19159*  |
| S7   | (ti,ab("gastro-oesophageal reflux disease" or "gastrooesophageal reflux disease")) | MEDLINE®  | 2125°   |
| S8   | S7 OR S6 OR S5 OR S4 OR S3 OR S2 OR S1                                      | MEDLINE®  | 30922*  |
| S9   | MJMESH.EXACT("Lansoprazole")                                                | MEDLINE®  | 168°    |
| S10  | (ti,ab(prevacid or lansoprazole))                                            | MEDLINE®  | 2315°   |
| S11  | S10 OR S9                                                                    | MEDLINE®  | 2337°   |
| S12  | MJMESH.EXACT("Omeprazole")                                                  | MEDLINE®  | 5012*   |
| S13  | (ti,ab(omeprazole or Prilosec or "Prilosec OTC" or Zegerid))                | MEDLINE®  | 8080*   |
| S14  | S13 OR S12                                                                   | MEDLINE®  | 9482*   |
| S15  | (s8 and (s11 or s14))                                                       | MEDLINE®  | 1367*   |
| S16  | (s15) and (human(yes) AND abany(yes) AND (la.exact("English")))            | MEDLINE®  | 576°    |
| S17  | (MJEMB.EXACT.EXPLODE("gastroesophageal reflux"))                            | Embase®   | 29433*  |
| S18  | ((ti,ab(GER OR GERD OR GORD)))                                               | Embase®   | 22079*  |
| S19 | ((ti,ab("acid reflux" or "chronic acid reflux"))) | Embase® | 4001° |
| S20 | ((ti,ab("heart burn and acid reflux"))) | Embase® | 2° |
| S21 | ((ti,ab("gastrooesophageal reflux disease" or "gastro esophageal reflux disease"))) | Embase® | 17584* |
| S22 | ((ti,ab("gastroesophageal reflux" or "gastro esophageal reflux"))) | Embase® | 29521* |
| S23 | ((ti,ab("gastro-oesophageal reflux disease" or "gastro oesophageal reflux disease"))) | Embase® | 2785° |
| S24 | S23 OR S22 OR S21 OR S20 OR S19 OR S18 OR S17 | Embase® | 50860* |
| S25 | MJEMB.EXACT("lansoprazole") | Embase® | 3242° |
| S26 | ((ti,ab(prevacid or lansoprazole))) | Embase® | 3626° |
| S27 | S26 OR S25 | Embase® | 4872° |
| S28 | MJEMB.EXACT("omeprazole") | Embase® | 11106* |
| S29 | ((ti,ab(omeprazole or Prilosec or "Prilosec OTC" or Zegerid))) | Embase® | 11958* |
| S30 | S29 OR S28 | Embase® | 16314* |
| S31 | (S24 and (S27 or S30)) | Embase® | 3012° |
| S32 | (S31) and (human(yes) AND abany(yes) AND (la.exact("English"))) | Embase® | 1419° |
| S33 | (S16 or S32) | Embase®, MEDLINE® | 1499° |

Medline was searched from 1946 to December 2019, Embase from 1947 to December 2019 and CENTRAL was searched from January 2010 to December 2019.
Table 1: Total number of studies identified from database searches

| Source | Number of hits | Total after de-duplication |
|--------|----------------|---------------------------|
| Pubmed | 576            |                           |
| Embase | 1,419          | 1,526                     |
| CENTRAL | 166             |                           |
### Table 2: Inclusion & exclusion criteria

| Category      | Inclusion criteria                                                                 | Exclusion criteria                                                                                                                                 |
|---------------|-------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------|
| Population    | • Adult patients (older than 18 years of age) with non-erosive esophageal reflux disease (NERD). | • Studies investigating patients without NERD  
• Studies on patients younger than 18 years of age with NERD.  
• Studies treating NERD symptoms in patients with other diseases |
| Outcomes      | • Primary symptoms included Heartburn and regurgitation.  
• Intragastric pH  
• Adverse effects | • Articles without relevant data on any of the outcomes of interest  
• Genetic profiling studies  
• Phenotype guided dosing studies  
• Prevalence studies  
• Studies assessing our interventions’ effect for Helicobacter Pylori gastritis or eradication.  
• Studies co-administering omeprazole or lansoprazole with other drugs (PPI or other)  
• Studies comparing our PPI with Chinese traditional medicine / herbal drug  
• Studies assessing the effect of combination therapies.  
• Studies comparing our interventions with surgical treatments. |
| Study design  | • Cohort studies  
• Case-control studies | • Letters to the editor  
• Narrative reviews |
| **Type of Studies**                  | **Studies**                                                                 |
|-------------------------------------|-----------------------------------------------------------------------------|
| Cross-sectional studies             | • Editorials                                                                |
|                                     | • Randomised controlled trials                                             |
|                                     | • Database studies                                                         |
|                                     | • Systematic reviews                                                       |
|                                     | • Crossover studies                                                        |
|                                     | • Expert opinions                                                          |
|                                     | • Case studies                                                              |
|                                     | • Case series                                                               |

| **Year of Publication**             | **Studies**                                                                 |
|-------------------------------------|-----------------------------------------------------------------------------|
|                                     | • From inception to 30\(^{th}\) Dec 2019 for Medline and Embase            |
|                                     | • Jan 2011 to Dec 2019 for CENTRAL                                          |
|                                     | • Studies before 1\(^{st}\) Jan 2011 and after 13\(^{th}\) Dec 2019 (for CENTRAL only) |

| **Language**                        | **Studies**                                                                 |
|-------------------------------------|-----------------------------------------------------------------------------|
| English language                    | • Non-English language                                                     |

| **Filter applied**                  | **Studies**                                                                 |
|-------------------------------------|-----------------------------------------------------------------------------|
| Human, Abstracts                    | • Non-English language                                                     |
Figure 2: Risk of Bias Graph

Review authors’ judgements about each risk of bias item presented as percentages across all included studies.

- Random sequence generation (selection bias)
- Allocation concealment (selection bias)
- Blinding of participants and personnel (performance bias)
- Blinding of outcome assessment (detection bias)
- Incomplete outcome data (attrition bias)
- Selective reporting (reporting bias)
- Other bias

Legend:
- Low risk of bias
- Unclear risk of bias
- High risk of bias
**Figure 3: Risk of bias summary**

Review authors' judgements about each risk of bias item for each included study

| Study               | Random sequence generation (selection bias) | Allocation of participants and personnel (selection bias) | Blinding of outcome assessment (detection bias) | Incomplete outcome data (attrition bias) | Selective reporting (reporting bias) | Other bias |
|---------------------|--------------------------------------------|--------------------------------------------------------|-----------------------------------------------|----------------------------------------|--------------------------------------|-----------|
| Arzoumandi 2019     | ☐                                          | ☐                                                      | ☐                                             | ☐                                      | ☐                                    | ☐         |
| Fass 2000           | ☐                                          | ☐                                                      | ☐                                             | ☐                                      | ☐                                    | ☐         |
| Funaki 2013         | ☐                                          | ☐                                                      | ☐                                             | ☐                                      | ☐                                    | ☐         |
| Howdon 2009         | ☐                                          | ☐                                                      | ☐                                             | ☐                                      | ☐                                    | ☐         |
| Janczewska 1998     | ☐                                          | ☐                                                      | ☐                                             | ☐                                      | ☐                                    | ☐         |
| Katz 2000           | ☐                                          | ☐                                                      | ☐                                             | ☐                                      | ☐                                    | ☐         |
| Katz 2001           | ☐                                          | ☐                                                      | ☐                                             | ☐                                      | ☐                                    | ☐         |
| Mirer 2010          | ☐                                          | ☐                                                      | ☐                                             | ☐                                      | ☐                                    | ☐         |
| Vivian 1999         | ☐                                          | ☐                                                      | ☐                                             | ☐                                      | ☐                                    | ☐         |
### Abbreviations

| Abbreviation | Description |
|--------------|-------------|
| GERD         | Gastroesophageal reflux disease |
| NERD         | Non-erosive esophageal reflux disease |
| EE           | Erosive esophagitis |
| RCT          | Randomised Controlled Trial |
| PPI          | Proton Pump Inhibitor |
| ERD          | Erosive reflux disease |
| Zn           | Zinc (a trace element) |
| IR-OME       | Immediate release omeprazole |
| LES          | Lower esophagus sphincter |
| CENTRAL      | Cochrane Central Register of Controlled Trials |